Brooke Davis

Equillium, Inc.

Equillium is a clinical-stage biotechnology company leveraging deep understanding of immunobiology to pioneer new products with a mission to dramatically improve the lives of patients with severe autoimmune and inflammatory diseases who continue to suffer with high unmet medical needs. By bringing treatments designed to restore the balance of the immune system, we hope to restore the balance of life for patients in need. Our lead product candidate, itolizumab, is a first-in-class monoclonal antibody that targets the CD6-ALCAM signaling pathway, which plays a central role in the activation and trafficking of pathogenic effector T cells that drive inflammation in a number of diseases. We believe itolizumab may have broad therapeutic utility and our current pipeline is focused on developing itolizumab as a best-in-class treatment for multiple severe immuno-inflammatory disorders – this includes acute graft-versus-host disease, SLE / lupus nephritis and uncontrolled asthma.